干扰素α对人骨肉瘤U2OS细胞化疗敏感性的影响

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (874 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effect of interferon-α (IFN-α) on chemosensitivity in osteosarcoma U2OS cells. Methods Cells were divided into control group, IFN-α group, Cisplatin group and IFN-α+Cisplatin group. After treatment for 72 hours, cell growth inhibition rate was determined by Trypan Blue exclude test. Apoptosis was evaluated with Hoechst 33258 staining and DNA ladder. Expressions of caspase-3, 8 and 9 were detected through Western blot. After pre-treatment with Z-VAD-FMK, cell was treated with Cisplatin or combination. Growth inhibition was determined with Trypan Blue exclude test. Results Cells growth inhibition rates in IFN-α group, Cisplatin group and IFN-α+Cisplatin group were higher than those in control group, cells growth inhibition rate in IFN-α+Cisplatin group was higher than that in Cisplatin group (P < 0.01). DNA ladder appeared in IFN-α+Cisplatin group. Compared with Cisplatin group, the expression of caspase-3, 8 and 9 in IFN-α+Cisplatin group was significantly increased (P < 0.01). Cells growth inhibition rate of IFN-α+Cisplatin+Z-VAD-FMK group was lower than that of IFN-α+Cisplatin group (P < 0.01). Conclusion IFN-α enhances chemosensitivity to Cisplatin in U2OS cells through caspase-dependent apoptosis.

Key words： Interferon-α Cisplatin Osteosarcoma Chemosensitivity Apoptosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Xiufang1 YUAN Xiangwei2▲ QIN Ying2 CHEN Zhongxian2

Cite this article:

HUANG Xiufang1 YUAN Xiangwei2▲ QIN Ying2 CHEN Zhongxian2. Effect of interferon-α on chemosensitivity in osteosarcoma U2OS cells[J]. 中国医药导报, 2021, 18(6): 23-26.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I6/23

[1] Carina V，Costa V，Sartori M，et al. Adjuvant biophysical therapies in osteosarcoma [J]. Cancers（Basel），2019，11（3）：348-353. doi：10.3390/cancers11030348.
[2] Botter SM，Neri D，Fuchs B. Recent advances in osteosarcoma [J]. Curr Opin Pharmacol，2014，16（1）：15-23. doi：10.1016/j.coph.2014.02.002.
[3] Zhang Y，Yang J，Zhao N，et al. Progress in the chemotherapeutic treatment of osteosarcoma [J]. Oncol Lett，2018，16（5）：6228-6237.doi：10.3892/ol.2018.9434.
[4] Zhang B，Zhang Y，Li R，et al. The efficacy and safety comparison of first-line chemotherapeutic agents （high-dose methotrexate，doxorubicin，cisplatin，and ifosfamide） for osteosarcoma：a network meta-analysis [J]. J Orthop Surg Res，2020，15（1）：51-58. doi：10.1186/s13018-020-1576-0.
[5] Manara MC，Serra M，Benini S，et al. Effectiveness of type Ⅰ interferons in the treatment of multidrug resistant osteosarcoma cells [J]. Int J Oncol，2004，24（2）：365-372.
[6] Lee M，Rhee I. Cytokine signaling in tumor progression [J]. Immune Netw，2017，17（2）：214-227. doi：10.4110/in.2017. 17.4.214.
[7] Gavrieli Y，Sherman Y，Ben-Sasson SA，et al. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation [J]. J Cell Biol，1992，119（3）：493-501. doi：10.1083/jcb.119.3.493.
[8] Ivashkiv LB，Donlin LT. Regulation of type Ⅰ interferon responses [J]. Nat Rev Immunol，2014，14（1）：36-49. doi：10.1038/nri3581.
[9] Stanifer ML，Pervolaraki K，Boulant S. Differential regulation of type Ⅰ and type Ⅲ interferon signaling [J]. Int J Mol Sci，2019，20（6）：1445-1450. doi：10.3390/ijms20061445.
[10] Morris R，Kershaw NJ，Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway [J]. Protein Sci，2018，27（12）：1984-2009. doi：10.1002/pro.3519.
[11] Gao Z，Zhu M，Wu Y，et al. Interferon-λ induces G1 phase cell cycle arrest and apoptosis in gastric carcinoma cells in vitro [J]. Oncol Rep，2014，32（1）：199-204. doi：10.3892/or.2014.3185.
[12] Post AEM，Smid M，Nagelkerke A. Interferon-stimulated genes are involved in cross-resistance to radiotherapy in tamoxifen-resistant breast cancer [J]. Clin Cancer Res，2018，24（14）：3397-3408. doi：10.1158/1078-0432.CCR-17-2551.
[13] Kanai T，Suzuki H，Yoshid H，et al. Significance of quantitative interferon-gamma levels in non-small-cell lung cancer patients’ response to immune checkpoint inhibitors [J]. Anticancer Res，2020，40（5）：2787-2793. doi：10.21873/anticanres.14251.
[14] Eit RE，Itani AR，Nassar F，et al. Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors [J]. Cancer，2019，125（16）：2818-2828. doi：10.1002/cncr.32130.
[15] Mattila K，Raanta P，Lahtela V，et al. Long-term survival of stage Ⅳ melanoma patients treated with BOLD combination chemotherapy and intermediate-dose subcutaneous interferon-alpha [J]. Anticancer Res，2018，38（11）：6393-6397. doi：10.21873/anticanres.12999.
[16] Makowska A，Wahab L，Braunschweig T，et al. Interferon beta induces apoptosis in nasopharyngeal carcinoma cells via the TRAIL-signaling pathway [J]. Oncotarget，2018，9（18）：14228-14250. doi：10.18632/oncotarget.24479.
[17] Tian Y，Wang ML，Zhao J. Crosstalk between autophagy and type Ⅰ interferon responses in innate antiviral immunity [J]. Viruses，2019，11（2）：130-138. doi：10.3390/v11020132.
[18] Provance OK，Lewis-Wambi J. Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer [J]. Breast Cancer Res，2019，21（1）：59-66. doi：10.1186/s13058-019-1140-1.
[19] Sandoval R，Xue J，Pilkinton M，et al. Different requirements for the cytostatic and apoptotic effects of type Ⅰ interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines [J]. J Biol Chem，2004， 279（31）：32275-32280. doi：10.1074/jbc.M313830200.
[20] Park YB，Park MJ，Kimura K，et al. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines [J]. Cancer Genet Cytogenet，2002，133（2）：105-111. doi：10.1016/s0165-4608（01）00575-1.
[21] Chen X，Wang KW，Chen YQ. Cisplatin induces apoptosis of A549 cells by downregulating peroxidase V [J]. Eur Rev Med Pharmacol Sci，2018，22（21）：7289-7295. doi：10.26355/eurrev_201811_16265.
[22] Larsen BD，S?覬rensen CS. The caspase-activated DNase：apoptosis and beyond [J]. FEBS J，2017，284（8）：1160-1170. doi：10.1111/febs.13970.
[23] Fritsch M，Günther SD，Schwarzer R，et al. Caspase-8 is the molecular switch for apoptosis，necroptosis and pyroptosis [J]. Nature，2019，575（7784）：683-687. doi：10.1038/s41586-019-1770-6.
[24] Wang Y，Xia C，Lun Z，et al. Crosstalk between p38 MAPK and caspase-9 regulates mitochondria-mediated apoptosis induced by tetra-α-（4-carboxyphenoxy） phthalocyanine zinc photodynamic therapy in LoVo cells [J]. Oncol Rep，2018，39（1）：61-70. doi：10.3892/or.2017.6071.
[25] Li YJ，Zhang GP，Zhao F，et al. Target therapy of TRIM-14 inhibits osteosarcoma aggressiveness through the nuclear factor-κB signaling pathway [J]. Exp Ther Med，2018，15（3）：2365-2373. doi：10.3892/etm.2017.5679.